Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117436005 | 11743600 | 5 | F | 20151029 | 20160713 | 20151116 | 20160720 | EXP | JP-GLAXOSMITHKLINE-JP2015JPN160873 | GLAXOSMITHKLINE | 24.87 | YR | F | Y | 42.00000 | KG | 20160720 | CN | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117436005 | 11743600 | 1 | PS | LAMICTAL | LAMOTRIGINE | 1 | Oral | 25 MG, QD | 325 | MG | 20241 | 25 | MG | TABLET | QD | ||||
| 117436005 | 11743600 | 2 | C | MERCAZOLE | CARBIMAZOLE | 1 | 5 MG, UNK | 0 | 5 | MG | |||||||||
| 117436005 | 11743600 | 3 | C | LEXAPRO | ESCITALOPRAM OXALATE | 1 | 10 MG, QD | 0 | 10 | MG | QD | ||||||||
| 117436005 | 11743600 | 4 | C | REFLEX | MIRTAZAPINE | 1 | 15 MG, QD | 0 | 15 | MG | QD | ||||||||
| 117436005 | 11743600 | 5 | C | FLUNITRAZEPAM | FLUNITRAZEPAM | 1 | 2 MG, QD | 0 | 2 | MG | QD | ||||||||
| 117436005 | 11743600 | 6 | C | SULPIRIDE | SULPIRIDE | 1 | 50 MG, BID | 0 | 50 | MG | BID | ||||||||
| 117436005 | 11743600 | 7 | C | PRIMPERAN | METOCLOPRAMIDE HYDROCHLORIDE | 1 | 5 MG, TID | 0 | 5 | MG | TID | ||||||||
| 117436005 | 11743600 | 8 | C | ALPRAZOLAM. | ALPRAZOLAM | 1 | 0.4 MG, TID | 0 | .4 | MG | TID | ||||||||
| 117436005 | 11743600 | 9 | C | ENSURE | AMINO ACIDSDEXTROSEELECTROLYTES NOSSOYBEAN OILVITAMINS | 1 | 250 ML, TID | 0 | 250 | ML | TID | ||||||||
| 117436005 | 11743600 | 10 | C | LOXONIN | LOXOPROFEN SODIUM | 1 | 60 MG, PRN | 0 | 60 | MG | |||||||||
| 117436005 | 11743600 | 11 | C | SAWACILLIN CAPSULES 250 | 2 | 250 MG, TID | 0 | 250 | MG | TID | |||||||||
| 117436005 | 11743600 | 12 | C | CALONAL | ACETAMINOPHEN | 1 | 200 MG, PRN | 0 | 200 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 117436005 | 11743600 | 1 | Bipolar disorder |
| 117436005 | 11743600 | 2 | Basedow's disease |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 117436005 | 11743600 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 117436005 | 11743600 | Neutrophil count decreased | |
| 117436005 | 11743600 | Pyrexia | |
| 117436005 | 11743600 | Rash generalised | |
| 117436005 | 11743600 | Urticaria |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 117436005 | 11743600 | 1 | 20151014 | 20151027 | 0 | |
| 117436005 | 11743600 | 2 | 20130410 | 0 | ||
| 117436005 | 11743600 | 4 | 20151109 | 0 | ||
| 117436005 | 11743600 | 6 | 20151109 | 0 | ||
| 117436005 | 11743600 | 7 | 20151109 | 0 |